Vaxcyte, Inc. (PCVX) Stock

Vaxcyte, Inc., headquartered in San Carlos, California, is a pioneering clinical-stage biotechnology company focused on developing innovative protein vaccines aimed at preventing and treating bacterial infectious diseases. Established in 2013 and originally known as SutroVax, the company rebranded as Vaxcyte in May 2020, underscoring its commitment to advancing vaccine research and development.

Central to Vaxcyte's pipeline is its lead vaccine candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials. This vaccine targets invasive pneumococcal disease and pneumonia, addressing critical public health needs associated with pneumococcal infections.

In addition to VAX-24, Vaxcyte is advancing other promising vaccine candidates including VAX-XP, designed to protect against emerging strains and combat antibiotic resistance, and VAX-A1, a conjugate vaccine candidate targeting Group A Streptococcus. The company also focuses on VAX-PG, a novel protein vaccine candidate targeting a keystone pathogen responsible for periodontitis, a severe form of gum disease.

Driven by a commitment to innovation and scientific excellence, Vaxcyte collaborates with leading research institutions and healthcare partners to accelerate the development of vaccines that address significant unmet medical needs globally. Through its cutting-edge technologies and strategic initiatives, Vaxcyte aims to revolutionize the prevention and treatment of bacterial infections, ultimately improving public health outcomes worldwide.